Claim Missing Document
Check
Articles

Found 2 Documents
Search

Expression of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) in Normal Wistar Rat Post-Cheral® Administration Asyhari, Firda Nuri; Zulfatim, Heni Sukma; Putri, Nenis Try Melani; Dliyauddin, Moh; Jamil, Ahmad Shobrun; Soewondo, Aris; Natsir, Muhammad Halim; Ibrahim, Mansur; Rahayu, Sri; Djati, Muhammad Sasmito; Rifa’i, Muhaimin
HAYATI Journal of Biosciences Vol. 31 No. 5 (2024): September 2024
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.31.5.1030-1036

Abstract

Maintaining immunoglobulin levels in the body is important to protect the body from exposure to pathogens. One effort can be made by consuming herbs containing immunomodulatory compounds, such as Cheral®, which includes a combination of herbs Phyllanthus niruri and Curcuma longa. This research aims to determine the expression of immunoglobulin M (IgM) and immunoglobulin G (IgG) following the administration of Cheral® to Wistar rats. The study was conducted in vivo, utilizing 24 healthy male Wistar rats for a 90-day treatment period. The research was divided into four treatment groups, including a control group and three dosage groups: Dose 1 (156.25 mg/kg BW), Dose 2 (312.5 mg/kg BW), and Dose 3 (468.75 mg/kg BW). IgM and IgG were isolated from the spleen and analyzed using flow cytometry. Flow cytometry data were analyzed using SPSS with a one-way ANOVA and post hoc test (p-value <0.05). The analysis showed that the relative number of IgM-producing cells in the control group was significantly higher than in the treatment groups, with a difference of 44.40%. In contrast, the relative number of IgG-producing cells in Dose 3 was significantly lower than all other treatment groups, showing a decrease of 29.21%. Overall, the expression of IgG and IgM did not differ substantially across all treatments. The lower IgG and IgM profiles compared to the control group indicate Cheral®'s ability to prevent infections and maintain the immune system of the rats throughout the treatment period.
Study of Flavonoid in Apium graveolens L. as a Kirsten Rat Sarcoma Protein Inhibitor in Colorectal Cancer Based on In Silico Study Abdullah, Abdullah; Putri, Nenis Try Melani; Rosyadah, Nuraini; Ramadhani, Putri; Putri, Siti Aqila Kharisma; Widyananda, Muhammad Hermawan; Kurniawan, Nia; Fatchiyah, Fatchiyah
Biotropika: Journal of Tropical Biology Vol. 11 No. 2 (2023)
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.biotropika.2023.011.02.07

Abstract

Colorectal cancer (CRC) is considered the second deadliest cancer, mainly caused by the mutation of Kirsten Rat Sarcoma (KRAS) type G12D; it’s still undruggable. Flavonoids are secondary metabolites in celery, consisting of apigenin, luteolin, quercetin, and kaempferol. This study aims to analyse the most potential flavonoid compounds in Apium graveolens L. as KRAS inhibitors in CRC with in-silico. This study starts by collecting the 3D structure, Compound ID, formula, and canonical SMILES of compounds from PubChem and the 3D structure of KRAS G12D from the RCSB-PDB. Ligand and protein preparations using OpenBabel PyRx and Biovia Discovery Studio 2019. The SwissADME web server is used to analyse drug-likeness, the PassOnline web server is used to analyse biological activity, docked using PyRx VinaWizard, and visualisation by Biovia Discovery Studio 2019. RMSD and RMSF values were obtained by analysing binding stability with the YASARA application. The molecular docking test showed that chrysoeriol, luteolin, and apigenin have the highest binding affinity and advance to molecular dynamic test. Results of the molecular dynamic showed that chrysoeriol could potentially inhibit the KRAS protein drug in CRC since it also had the lowest toxicity and the strongest binding affinity to the KRAS.